We collaborate with patient advocacy platforms to promote quality medical care and services and to improve and expand educational and outreach efforts.
It is our mission to discover, develop and deliver innovative therapies that help to improve patients' quality of life.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
We are committed to helping improve the quality of life for those who use our therapies.
CSL Behring provides a wide range of treatments for people with rare or life-threatening illnesses.
Popular search terms:
Volunteers leave the office to lend a hand at centre, hospice and nature reserve.
Eduardo Cabas is new General Manager of CSL Behring UK and Ireland, succeeding Christian Wieszner.
For HAE Day, we take a look at the impact of this rare disease, which causes painful swelling, on the one in 50,000 people wh…
Monday, April 17 is World Haemophilia Day. It’s a day to highlight the experiences of people living with this life-long inher…
A rare disease is defined as one that affects fewer than one person in every 2,000. But more than 6,000 rare diseases have be…
The entire UK CSL Behring business left the office for a special Community Day to provide voluntary work for two local charit…
Volunteers from CSL Behring transformed a community centre near their office which is a meeting place for Ukrainian refugees …
Dr Ellie Karampini, a post-doctoral researcher at the Royal College of Surgeons in Ireland, has received a CSL Behring Prof H…
CSL Behring UK has become a full member of the Association of the British Pharmaceutical Industry (ABPI).
Americas
Asia Pacific
Middle East
Europe
